Seven updates in colorectal cancer
In February 2000, former president Bill Clinton dedicated March as National Colon Cancer Awareness Month.
Colorectal cancer is the second-leading cause of cancer deaths; however, nearly one-third of eligible adults aged 50 to 75 years have not been screened.
As a result, the CDC has launched the “Screen for Life” campaign to offer updated materials on the screening of colorectal cancer.
To coincide with Colorectal Cancer Awareness Month, HemOnc Today presents seven updates in the screening and treatment of colorectal cancer.
- Nearly one in 10 patients with colorectal cancer harbored mutations in genes that may increase susceptibility to cancer, suggesting the need for an expanded role of genetic testing in the treatment of the disease and in disease prevention for at-risk family members. Read more.
- Adults born in 1990 appeared twice as likely to be diagnosed with colon cancer and four times as likely to be diagnosed with rectal cancer as people born in 1950. Further, three in 10 rectal cancer diagnoses occur in patients aged younger than 55 years. Read more.
- The prognostic impact of tumor-infiltrating lymphocytes for colorectal cancer differed based on primary tumor site. Results showed high density of tumor-infiltrating lymphocytes (TILs) was most associated with improved outcomes among patients with right-sided tumors. Read more.
- BRAF –mutated advanced colorectal cancer is linked to a worse prognosis than BRAF wild-type disease, independent of other clinicopathological features known to be prognostic. Read more.
- Individuals who consumed foods rich in dietary fiber and whole grains showed a decreased risk for F. nucleatum–positive colorectal cancer, but not a lower risk for F. nucleatum–negative cancer. Read more.
- Rectal and left-sided colon cancers are not clearly delineated by location, but rather are characterized by a range of distinct molecular variations, a phenomenon that has implications for developing tailored treatments in the future. Read more.
- Long-term use of aspirin reduced risk for colorectal cancer but increased risk for gastrointestinal bleeding, highlighting the need to weigh the risks and benefits of prophylactic aspirin use. Read more.